Literature DB >> 19906243

Conference summary and conclusions. A comprehensive approach to predicting and managing mood effects of glucocorticoids.

Esther M Sternberg1, Lewis L Judd.   

Abstract

The discovery of glucocorticoids and their enormous therapeutic benefits led to the use of these compounds as valuable medications for a wide variety of diseases. In 1950 this effort was ushered in by a landmark event-the awarding of the 1950 Nobel Prize in Physiology and Medicine to Drs. Phillip Hench, Edward Kendall, and Tadeus Reichstein. It was Hench who described and researched the successful use of the glucocorticoid, cortisone, and pituitary adrenocorticotrophic hormones to treat rheumatoid arthritis. Significant scientific discovery preceded Hench and colleagues' efforts, but the revolutionary accumulation of discovery in glucocorticoids since then is one of the unique scientific stories in the history of medicine. The scientific conference upon which this volume is based represents an attempt to convene a state-of-the-science meeting on the current understanding and scientific status of this fascinating, far-reaching, and fast-moving field. This last chapter will summarize the exciting presentations of this 2-day conference.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19906243      PMCID: PMC2933141          DOI: 10.1111/j.1749-6632.2009.05059.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  Use of oral corticosteroids in the United Kingdom.

Authors:  T P van Staa; H G Leufkens; L Abenhaim; B Begaud; B Zhang; C Cooper
Journal:  QJM       Date:  2000-02

2.  Glucocorticoids and mood: clinical manifestations, risk factors and molecular mechanisms. Proceedings of a meeting. June 20-21, 2008. La Jolla, California, USA.

Authors: 
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 3.  Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders.

Authors:  George P Chrousos; Tomoshige Kino
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

4.  Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey.

Authors:  Hyon K Choi; John D Seeger
Journal:  Arthritis Rheum       Date:  2005-08-15

5.  Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study.

Authors:  L J Walsh; C A Wong; M Pringle; A E Tattersfield
Journal:  BMJ       Date:  1996-08-10

Review 6.  Role of CRF receptor signaling in stress vulnerability, anxiety, and depression.

Authors:  Richard L Hauger; Victoria Risbrough; Robert H Oakley; J Alberto Olivares-Reyes; Frank M Dautzenberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 7.  Mechanisms generating diversity in glucocorticoid receptor signaling.

Authors:  Javier R Revollo; John A Cidlowski
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 8.  Glucocorticoid receptor polymorphisms in major depression. Focus on glucocorticoid sensitivity and neurocognitive functioning.

Authors:  Anne T Spijker; Elisabeth F C van Rossum
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 9.  Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.

Authors:  Andrea H Marques; Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 10.  Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy.

Authors:  E Sherwood Brown
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

View more
  1 in total

1.  Hippocampal volume in healthy controls given 3-day stress doses of hydrocortisone.

Authors:  E Sherwood Brown; Haekyung Jeon-Slaughter; Hanzhang Lu; Rhoda Jamadar; Sruthy Issac; Mujeeb Shad; Daren Denniston; Carol Tamminga; Alyson Nakamura; Binu P Thomas
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.